NSP 6783

Drug Profile

NSP 6783

Latest Information Update: 07 Nov 2003

Price : $50

At a glance

  • Originator Nippon Kayaku; Signal Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Peripheral nervous system diseases

Most Recent Events

  • 31 Jul 2000 Discontinued - Preclinical for Peripheral nervous system diseases in USA (unspecified route)
  • 31 Jul 2000 Discontinued - Preclinical for Peripheral nervous system diseases in Japan (unspecified route)
  • 28 Feb 1997 Preclinical development for Peripheral nervous system diseases in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top